Amur Minerals (GB:CRTX) has released an update.
CRISM Therapeutics Corporation, a UK-based company specializing in localized chemotherapy drug delivery, is set to announce its interim results for the first half of 2024 on September 19. Interested investors are invited to a live presentation by the CEO, Andrew Webb, with an opportunity to submit questions. Additionally, CRISM is progressing towards a clinical trial application for its pioneering ChemoSeed product in the treatment of high-grade glioma.
For further insights into GB:CRTX stock, check out TipRanks’ Stock Analysis page.
